Skip to content

Calculus exits Mologic – generating up to a 3.6x return for investors

Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Calculus successfully exit Mologic by sale to new philanthropic entity Global Access Health London 19 July 2021: Calculus Capital (“Calculus”), pioneers of the tax efficient investment … Continued

Calculus VCT Annual General Meeting 2021

The Annual General Meeting (AGM) of Calculus VCT plc (the “Company”) will be held at 12.30pm on 8 July 2021. The AGM is an important event in the Company’s corporate calendar, providing an opportunity for shareholders to meet the board and put questions to the directors and the investment manager, as well as enabling shareholders … Continued

Calculus invests in Spectral MD

Calculus VCT has invested £0.5m into Spectral MD through an oversubscribed inital public offering onto AIM, on Tuesday 22 June. The Dallas-based firm, which is building notable presence in the UK as part of its product launch effort, produces predictive analytics, proprietary AI algorithms and imaging systems to assist with medical treatment. Spectral MD’s technology, … Continued

Calculus invests in Arecor following successful IPO

Arecor announced its admission to trading on AIM, a market operated by London Stock Exchange, on 3 June 2021. Admission follows a successful oversubscribed placing by Panmure Gordon, raising gross proceeds of £20 million at a price of 226 pence per share. On Admission the Company will have a market capitalisation of approximately £62.5 million. … Continued

Calculus Exits Sports Tour Operator inspiresport

inspiresport is the industry leading sports development tour operator, offering unrivaled access to world class clubs, coaches, and facilities to take young players of all abilities on extraordinary sporting journeys. The company has been acquired by Portman Travel Group, which is expanding into the sports travel market, providing an exit event for Calculus investors. Calculus, … Continued

Arecor granted key US patent

Cambridge, UK., 13 May 2021 – Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the grant by the United States Patent and Trademark Office of U.S. Utility Patent No. 10,925,965 B2, a patent that contributes to the Company’s global patent portfolio underpinning its ArestatTM technology … Continued

Calculus invests in Invizius

The University of Edinburgh spin-out is developing potentially lifesaving products that help reduce complications and high death rates amongst dialysis patients. Incoming institutional investor Calculus Capital has participated in a funding round with existing investors Downing Ventures and Mercia, alongside Solvay Ventures, Scottish Enterprise and Old College Capital Glasgow, Scotland, May 6th, 2021 – Invizius … Continued

Blu Wireless accelerates growth with opening of new US business entity

Business expansion and appointment of local team will enable Blu Wireless to accelerate growth in the defence, public safety, and transport sectors, providing enhanced customer service in North America. Blu Wireless, the leader in 5G mmWave networking equipment, has today announced the expansion into the United States with the launch of Blu Wireless Technology Inc. … Continued

C4X signs exclusive worldwide licensing agreement with Sanofi worth up to €414 million

The licensing agreement, which C4X will receive an upfront payment of €7 million from, is for their oral pre-clinical IL-17A inhibitor programme. 12 April 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that its subsidiary, C4X Discovery Limited (“C4XD”, “C4X Discovery” or the “Company”), has signed an exclusive worldwide licensing agreement with … Continued

Arecor receives £2.8 million grant award from Innovate UK

Coveted award for Phase II clinical development of lead product, AT247, its next generation ultra-rapid acting Insulin Cambridge, UK., 31st Mar 2021: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has been awarded a £2.8 million grant from Innovate UK to support the … Continued